Ruxolitinib (PV — HU-resistant / intolerant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-RUXOLITINIB` `DRUG-ASPIRIN`

ID	`REG-RUX-PV`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MPN-2015` `SRC-NCCN-MPN-2025` `SRC-RESPONSE-VANNUCCHI-2015`

Notes

2L PV after HU resistance / intolerance per ELN criteria. RESPONSE trial: composite Hct + spleen response 21% vs 1% with best available therapy. NEVER abrupt-stop — taper over ≥1-2 weeks. HBV / TB / HSV screening mandatory pre-initiation. STUB — requires clinical co-lead signoff before publication.

Used By

Indication

IND-PV-2L-RUXOLITINIB - IND-PV-2L-RUXOLITINIB